NuVasive in Strong Position to Weather the COVID-19 Storm

NuVasive suffered modest impact from COVID-19 in 1Q20 and expects severe reductions in 2Q. However, the company is using its strong cash position to push forward with product development.

Vericel Confident in Near-Term MACI Recovery

Vericel’s MACI revenue grew 22% in 1Q20 despite mid-March disruptions from COVID-19. The company believes it has passed the market low point and remains confident it will recoup most lost procedures.

COVID-19 Derails SI-BONE’s Record Procedure Trajectory in 1Q20

The company grew in the low double digits in 1Q20 but was on pace for record procedure volumes before COVID-19 impacted the U.S. orthopedic market in mid-March.

Stryker Confident in Orthopedics’ Ability to Bounce Back from COVID-19

While Stryker anticipates significant disruption to orthopedic sales in 2Q20, the company is confident the revenue-generating ability of orthopedics will drive the recovery of deferred procedures.

ConMed Foresees Dramatic Virus-Related Declines in 2Q20

The company declined 12.5% in 1Q20 and believes the market low point will be in the second quarter. ConMed's orthopedic sales for April are projected to decline by 65%.